Amgen has reported findings from a real-world study where Prolia (denosumab) injection demonstrated significant reduction in osteoporotic fracture risk in postmenopausal women compared to alendronate.
The observational, retrospective study has enrolled 478,651 postmenopausal women aged 66 or above who previously did not receive any osteoporosis treatment.
Out of the total, 89,115 patients were treated with Prolia and the remaining received oral alendronate, a bisphosphonate treatment.
The study demonstrated that relative risk of fracture across various fracture types were reduced in patients using Prolia.
Furthermore, greater reduction in major osteoporotic (MOP) fracture risk was observed in patients using Prolia for longer duration.
Amgen vice-president and General Medicine global medical therapeutic area head Jyothis George said: “Amgen has long been committed to reducing the impact of osteoporosis, an underdiagnosed and undertreated disease that increases the risk for bone loss and fracture for millions of post-menopausal women.
“May is Osteoporosis Awareness and Prevention Month, making this a great time to share these new data about Prolia and the important role it can play in reducing the risk of potentially life-altering fractures in these women at high risk for fracture.”
Prolia targeting RANK Ligand, an essential regulator of bone-removing cells, is approved for use in over 80 countries globally.
It is also indicated for increasing bone mass in men with osteoporosis and treating glucocorticoid-induced osteoporosis in men and women.